OPKO Health, Inc. Effective Income Tax Rate Reconciliation Gilti Percent
OPKO Health, Inc. (OPK) reported Effective Income Tax Rate Reconciliation Gilti Percent of 441.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent · last filed 2026-02-26
- OPKO Health, Inc. effective income tax rate reconciliation gilti percent for fiscal 2024 was 441.70%, a 2884.46% increase from fiscal 2023.
- OPKO Health, Inc. effective income tax rate reconciliation gilti percent for fiscal 2023 was 14.80%, a 202.04% increase from fiscal 2022.
- OPKO Health, Inc. effective income tax rate reconciliation gilti percent for fiscal 2022 was 4.90%.
- OPKO Health, Inc. effective income tax rate reconciliation gilti percent for fiscal 2021 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation Gilti Percent 12 month |
|---|---|
| 2024-12-31 | 441.70% 10-K · filed 2026-02-26 |
| 2023-12-31 | 14.80% 10-K · filed 2026-02-26 |
| 2022-12-31 | 4.90% 10-K · filed 2025-03-03 |
| 2021-12-31 | 0.00% 10-K · filed 2024-03-01 |
| 2020-12-31 | 0.00% 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |